Insider · CIK 0001829630
John Vavricka
officer
Files at AVIR (Atea Pharmaceuticals, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 31, 2026 | AVIR Atea Pharmaceuticals, Inc. | MOption exercise Common Stock | +42,083 | - | - | 94,164 | Feb 3, 2026 |
| Jan 31, 2026 | AVIR Atea Pharmaceuticals, Inc. | FTax withholding Common Stock | -11,570 | $4.24 | $49k | 82,594 | Feb 3, 2026 |
| Jan 31, 2026 | AVIR Atea Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -33,333 | $0.00 | $0 | 0 | Feb 3, 2026 |
| Jan 31, 2026 | AVIR Atea Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -8,750 | $0.00 | $0 | 0 | Feb 3, 2026 |
| Jan 31, 2026 | AVIR Atea Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +119,520 | $0.00 | $0 | 119,520 | Feb 3, 2026 |
| Jan 31, 2025 | AVIR Atea Pharmaceuticals, Inc. | MOption exercise Common Stock | +33,333 | - | - | 54,848 | Feb 4, 2025 |
| Jan 31, 2025 | AVIR Atea Pharmaceuticals, Inc. | AGrant or award Common Stock | +8,750 | - | - | 63,598 | Feb 4, 2025 |
| Jan 31, 2025 | AVIR Atea Pharmaceuticals, Inc. | FTax withholding Common Stock | -11,517 | $3.06 | $35k | 52,081 | Feb 4, 2025 |
| Jan 31, 2025 | AVIR Atea Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -33,333 | $0.00 | $0 | 33,333 | Feb 4, 2025 |
| Jan 31, 2025 | AVIR Atea Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +8,750 | $0.00 | $0 | 8,750 | Feb 4, 2025 |
| Jan 31, 2025 | AVIR Atea Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +132,800 | $0.00 | $0 | 132,800 | Feb 4, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.